Laborie is set to exit the medical device manufacturer after another of its investors, Olympus, announced its intention to pay $260m for its remaining shares.

Osage University Partners has thrown its weight behind a series A2 round for Artizan, which is advancing work undertaken at Yale University.

Biohaven Therapeutics co-led Artizan Biosciences' latest round as part of an option and licensing agreement focusing on its inflammatory bowel disease drug candidates.

Xenotransplantation technology developer eGenesis has raised $125m in a series C round backed by Osage University Partners.

The Vertex Pharmaceuticals-backed genomic analytics platform developer has now raised approximately $88m in funding altogether.

GV returned to help heart disease drug developer Tenaya boost its overall funding to approximately $248m.

Oxford Sciences Innovation has returned to back a $30m funding round for Genomics, having previously contributed to a 2018 series B round.

Eli Lilly-backed inflammatory disease drug developer has filed to raise up to $100m in an initial public offering in the United States.

IP Group and V-Bio have backed a round that will support phase 2 trials for a treatment for diabetic macular edema.

Hovione Scientia and Consort Medical-backed Oxular has secured funding that will support phase 2 trials for a treatment for diabetic macular oedema.